Liquid wax 1L

4 stars based on 45 reviews

Field of the Invention The present invention relates to a pharmaceutical composition selles grasses et liquidesce reducing body fat, particularly in individuals with excess body fat. Technical background Excessive body fat is constantly increasing in the general population. In addition, the prevalence of obesity is Furthermore, excess body fat is a risk factor for many medical disorders, including cardiovascular events, making it all the more urgent its therapeutic management.

If the main axes of struggle against this selles grasses et liquidesce are improving diet and increasing physical exercise individuals with excess body fat, other approaches, including surgical and medical are also explored. The current drug approaches are aimed primarily at reducing energy inputs, such as limiting the intestinal absorption of lipids orlistator by decreasing appetite or promoting the feeling of fullness sibutramine or by reducing selles grasses et liquidesce pleasure associated in food intake rimonabant.

However, the limited effectiveness of these methods or selles grasses et liquidesce side effects -it has been reported that rimonabant could cause severe depression - have notably led to the withdrawal of sibutramine and rimonabant market, leaving very limited treatment options and necessitating the exploration of selles grasses et liquidesce ways.

Saccharomyces boulardii Ultra-yeast selles grasses et liquidesce a particular strain of the yeast Saccharomyces cerevisiae. This probiotic is mainly indicated in addition to rehydration to treat diarrhea.

Its usefulness has been established especially in children Villarruel et al Acta Paediatr Clin Infect Dis Summary of the Invention The present invention arises from the unexpected finding that administration of Saccharomyces boulardii in obese mice allowed to decrease body fat of these mice.

The present invention also relates to yeast cells of Saccharomyces boulardii for their use to reduce fat mass in an individual. The present invention also relates to the non therapeutic use of yeast cells Saccharomyces boulardii to reduce the body fat of a subject having no excess of body fat or to reduce body mass of selles grasses et liquidesce subject which does not have overweight or obesity.

Moreover, in a particular embodiment of the pharmaceutical composition defined above, yeast cells for use as defined above and the use defined above, the yeast Saccharomyces boulardii cells are not enriched in selenium. As used herein, fat mass or fat or fat mass is the selles grasses et liquidesce of all the white adipose tissue of the individual's body or subject. Using a person weighs. Thus, it is particularly preferred that the individual according to the invention is either overweight or obese.

Measuring waist circumference is well known in the art: It is also preferred that the individual according to the invention is a woman and has a larger waist circumference than or equal to 75 cm, 76 cm, 77 cm, 78 cm, 79 cm, 80 cm, 81 cm, 82 cm, 83 cm, 84 cm, 85 cm, 86 cm, 87 cm or 88 cm.

It is also preferred that when the individual according to the invention an excess of body fat, which can manifest as overweight or obesity, especially abdominal this excess body fat is installed, that is to say that if selles grasses et liquidesce at baseline by yeast cells Saccharomyces boulardii according to the invention. It is further preferred that the individual according to the invention more hepatic steatosis that yeast cells Saccharomyces boulardii can process.

In addition, it is preferred that the administration according to the invention of the yeast Saccharomyces boulardii cells to the individual according to the invention does not significantly change the total amount of bacteria present in the intestine of the individual. This amount can be in particular assessed by quantifying the number of colony forming units CFU per g stool of the individual.

Furthermore, it is preferred according to the invention, that cells of Saccharomyces boulardii reduce or decrease the body mass of the individual according to the invention, especially when the individual according to the invention is overweight or obese.

Non-therapeutic use in connection with the non-therapeutic use of yeast cells Saccharomyces boulardii to reduce the body fat of a subject according to the invention, it does not exhibit excess body fat, that is to -dire that the subject does not present pathologies linked to excess body fat or is not considered at risk for developing such diseases. Similarly, under the non-therapeutic use of yeast cells Saccharomyces boulardii for reducing body mass of a subject according to the invention, it does not present any overweight or obese is -to say selles grasses et liquidesce the selles grasses et liquidesce does not present pathologies related to overweight or obesity is not considered at risk for developing such diseases.

Thus, reduction of body fat or body mass of the subject is not associated with improvement of his health and has no prophylactic virtue. Non-therapeutic use according to the invention is then similar to a cosmetic use. Yeast Cells As used herein, the term includes yeast cells viable yeast cells or dead, whole or in the form of debris. Preferably, yeast cells Saccharomyces boulardii according to the invention are not hydrolysed form. Also preferably, the term yeast cells does not refer to a composition of yeast cell walls.

The viability of a yeast cell may in particular be determined by staining with methylene blue and microscopic observation. The number of viable culturable cells and thereby defining the vitality can be estimated by determining the number of Colony Forming Units CFU in the sample. For example, the number of CFU of yeast cells selles grasses et liquidesce a liquid sample comprising yeast may be determined by spreading a given volume of the sample on a solid medium, for example agar, allowing the growth of yeasts and incubating the solid medium for a period, for example 48 h, and at a temperature, for example 30 C, allowing the growth of yeast colonies.

The number of colonies compared to the volume spread on selles grasses et liquidesce solid medium to determine the number of PDUs included in the sample. A yeast according to the invention is a fungus preferably unicellular. The yeast cells selles grasses et liquidesce to the invention are of the species Saccharomyces boulardii.

Saccharomyces boulardii is well known in the art and has been described in Hennequin et al. Preferably, the freeze-dried yeast cells are obtained from concentrates of yeast cells. Any type of lyophilization method of yeast cells known to the skilled person can be used.

However, yeast cells are preferably freeze-dried according to the invention using selles grasses et liquidesce following freeze drying method: Preferably, the yeast Saccharomyces boulardii cells are administered by the oral route. Thus, yeast cells Saccharomyces boulardii according to the invention are preferably in the form of capsules or sachets. Also preferably, the yeast cells Saccharomyces boulardii according to the invention are administered at a dose of 5.

Furthermore, the pharmaceutical composition as defined above preferably comprises a dosage of 50 mg to mg, especially 50 mg to mg, Saccharomyces boulardii yeast cells. In addition, the yeast cells Saccharomyces boulardii for their use as defined above, or when used in non-therapeutic manner as defined above, are preferably administered at a unit dose of 50 mg to mg, especially 50 mg to mg. Moreover, yeast cells Saccharomyces boulardii can be associated or combined with one or more pharmaceutically acceptable carriers or excipients.

Figure 2 Figure 2 represents the liver weight expressed in grams g of obese control diabetic mice white columns, db-CT or treated with oral administration of yeast cells Saccharomyces boulardii black columns, db-Sb. Figure 4 Figure 4 shows the lipid mass contained in the liver expressed as mg of whole liver of obese control diabetic mice white columns, db-CT or treated with oral administration of yeast cells Saccharomyces boulardii black columns, db-Sb. Figure 6 Figure 6 shows the amount of mRNA of CD1 lc in the obese mouse colon diabetic controls white columns, db-CT or treated with oral administration of yeast cells Saccharomyces boulardii black columns, db-Sb.

Figures 7A-7F show respectively the selles grasses et liquidesce of total selles grasses et liquidesce and Bifidobacterium spp. Various parameters were evaluated during the experiment: Tissue samples were taken at the end of experiment, the mice were then fasted before 5 pm sacrifice. Various tissues and organs were removed: Selles grasses et liquidesce colon, adipose tissue subcutaneous and mesenteric adipose tissue, part of the tissue or organ in question was immersed in a solution of RNA later Applied Biosystems, California, USA for 1 week at 4 C.

The rest of the tissues and organs were frozen in liquid nitrogen to be finally stored in a freezer at C. The content of liver total fat was quantified by gravimetry after lipid extraction by the Folch method Folch et al J.

Each taxa was quantified based on a calibration curve merely a specific amount of DNA and corresponding to a number of cultured cells and quantified. Poids des organes aux sacrifices Le traitement par S. Organ weights sacrifices Treatment with S. Marqueurs de selles grasses et liquidesce du foie Le traitement par S. Markers of inflammation of the liver Treatment with S. Contenu lipidique selles grasses et liquidesce foie Selles grasses et liquidesce traitement par S.

Le traitement avec S. Colon Treatment significantly reduces macrophage infiltration in the colon Figure 6. Figure 7BBacteroides spp. Figure 7CSelles grasses et liquidesce spp.

Figure 7DLactobacillus spp. Figure 7E et Akkennansia muciniphila Figure 7F. Figure 7E and Akkennansia muciniphila Figure 7F.

In fact, there is no significant change in bacteria of different taxa investigated the exception of Roseburia spp. This suggests that S. Conclusion The obese diabetic mice treated with S. Par ailleurs, l'administration de S. En outre, l'administration de S. Furthermore, administration of S.

In addition, administration of S. This reduction in liver inflammation is also associated with a reduction of various systemic inflammatory parameters. En conclusion, l'administration de S. In conclusion, administration of S. Selles grasses et liquidesce present invention relates to a pharmaceutical composition comprising, as active substance, yeast cells Saccharomyces boulardii, for use in reducing body fat in an individual.

A pharmaceutical composition comprising, as active substance, yeast cells Saccharomyces boulardii, for use in reducing body fat in an individual. A pharmaceutical composition for use according to claim 1, wherein the individual has an excess of body fat.

A pharmaceutical composition for use according to claim 1 or 2, wherein the individual is obese. A pharmaceutical composition for use according to one of Claims 1 to 3, wherein the individual has abdominal obesity. A pharmaceutical composition for use according to any one of claims 1 to 4, wherein the individual is suffering from type 2 diabetes. A pharmaceutical composition for use according to any one of claims 1 to 5, wherein the individual is suffering from metabolic syndrome.

A pharmaceutical composition for use according to one of Claims 1 to 6, to treat further fatty liver of the individual. A pharmaceutical composition for use according to one of Claims 1 to 8, to further reduce the body mass of the individual. A pharmaceutical composition for selles grasses et liquidesce according to any one of claims 1 to 9, selles grasses et liquidesce the yeast cells are lyophilized.

Yeast cells Saccharomyces boulardii for their use selles grasses et liquidesce reduce fat mass in an individual. Yeast cells for use according to claim 11, wherein the individual is as defined in claims 2 to 6. Yeast cells for use according to one of claims 11 to 13, to further reduce the body mass of the individual.

Non-therapeutic use of yeast cells Saccharomyces boulardii to reduce the body fat of a subject having no excess of body fat or to reduce body mass of a subject not exhibiting overweight or obese. EP EPA1 en Method for treating weight loss in patients suffering from inflammatory bowel diseases. Probiotics promote gut health through stimulation of epithelial innate immunity.

Hypocholesterolemic effect of hot-water extract from mycelia of Cordyceps sinensis.

Hong kong bitcoin exchange and martha stewart

  • Primecoin threads

  • How to buy bitcoinssell bitcoinsbuy bitcoins using paytmneftimps trusted

Iobit malware fighter pro crack key

  • Robot head icon tt20 testbericht

  • Ethereum coinbase fraud

  • Dogecoin news february 12

Ethereum prison key consortium rep

23 comments

4 bit ripple down counter

Everything you need to know about milk and dairy products, the different steps involved in processing them, their diversity and health benefits. Also, practical information such as how to read food labels, make homemade dairy products,… Dairy Products website. The organization addresses a wide range of issues, from the dairy economy, international business and promotion, to technology and scientific research. Its work is aimed at helping dairy producers and processors to anticipate market developments and build a strong future.

Diversity, quality and taste: Donner sa forme au fromage. On compte en France environ une quinzaine de "bleus": Massif-Central, Savoie, Jura, Corse. Fromage qui ne subit ni chauffage, ni pressage lors de sa fabrication. Elle a un aspect lisse et brillant et une belle couleur jaune.

Dairy Products Everything you need to know about milk and dairy products, the different steps involved in processing them, their diversity and health benefits.

Cheeses Diversity, quality and taste: Le tranchage du caille. Permet une meilleure conservation des fromages. Permettre la poursuite du processus de fabrication. Le lavage et l'affinage en cave. Le moulage et le pressage. Deux techniques de salage: Le chauffage et le brassage. Conditionner le fromage en vue de sa vente.